Cantillo, E., Zemla, T., Moroney, J., Alvarez, E., Yauch, L., Lin, Y., … Slomovitz, B. (2022). TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC). In International Journal of Gynecological Cancer (Vol. 32, pp. A227–A228). Elsevier BV. https://doi.org/10.1136/ijgc-2022-igcs.519

Cantillo, Evelyn, Tyler Zemla, John Moroney, Edwin Alvarez, Lauren Yauch, Yvonne Lin, Michelle Brockman, et al. “TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC).” In International Journal of Gynecological Cancer, 32:A227–28. Elsevier BV, 2022. https://doi.org/10.1136/ijgc-2022-igcs.519.

Cantillo E, Zemla T, Moroney J, Alvarez E, Yauch L, Lin Y, et al. TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC). In: International Journal of Gynecological Cancer. Elsevier BV; 2022. p. A227–8.

Cantillo, Evelyn, et al. “TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC).” International Journal of Gynecological Cancer, vol. 32, Elsevier BV, 2022, pp. A227–28. Crossref, doi:10.1136/ijgc-2022-igcs.519.

Cantillo E, Zemla T, Moroney J, Alvarez E, Yauch L, Lin Y, Brockman M, Dilallo G, Liu J, Secord AA, Nixon A, Mandrekar S, Matulonis U, Kozono D, Slomovitz B. TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC). International Journal of Gynecological Cancer. Elsevier BV; 2022. p. A227–A228.